AHAkihiro Hisaka

Akihiro Hisaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akihiro Hisaka has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Hiromi Sato

    Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences Chiba University Chiba Japan

    12 shared publications
  • Hideki Yoshioka

    Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan

    9 shared publications
  • Hiromi Sato

    Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan

    8 shared publications
  • Hiroshi Suzuki

    Executive Director, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan

    8 shared publications
  • Hiroto Hatakeyama

    Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan

    7 shared publications
  • Yuta Tamemoto

    Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-city 260-8675, Chiba, Japan

    4 shared publications

Latest Publications

  • Open Access

    Photothermal Therapy-Induced Immunogenic Cell Death Synergistically Enhances the Therapeutic Effect of Immune Checkpoint Inhibitors

    by Shogo Yasuda, Yui Horikawa, Mei Ohashi, Mai Amou, Taisei Kanamori, Duan Runjing, Yuta Tamemoto, Wei Xu, Takuro Niidome, Akihiro Hisaka, et al.

    Background/Objectives: To improve the response rate of immune checkpoint inhibitors (ICIs), inducing immunogenic cell death (ICD) is a promising approach. Photothermal therapy (PTT) induces immunogenic cell death and activates anti-tumor immunity. While there are various ICD inducers, the difference in ICD induction by various modalities is poorly understood. In this study, we found previously unrecognized advantages of PTT compared to anti-cancer drugs and showed the usefulness of PTT as an anti-cancer drug-free approach to be combined with immunotherapy. Methods: Gold nanorods were synthesized as photothermal agents and added to culture medium or locally administered to tumor tissues. Mitoxantrone (MIT), an ICD inducer, and cisplatin (CDDP), a non-ICD inducer, were compared with PTT. To assess the induction of ICD, the subcellular localization and amounts of high mobility group box 1 (HMGB1) and calreticulin (CRT) were observed using immunofluorescent staining. FM3A tumor-bearing mice were treated with PTT or anti-cancer drugs, and cell death and DAMPs localization in tumor tissues were analyzed. Also, the supra-additive effect of PTT on ICI was observed. Tumor-infiltrating CD8+ T cells were examined to evaluate the immune status in tumor tissues. Results: In vivo assays showed that PTT induces HMGB1 release and increased expression of CRT on the cell membrane. Moreover, PTT showed a supra-additive effect in terms of therapeutic effect and anti-tumor activation when combined with an immune checkpoint inhibitor. Conclusions: In this study, we demonstrated that PTT induced ICD-related signaling and improved the response rate of ICI, which means PTT is a promising combination therapy with ICI.


  • Open Access

    Development of a Novel Machine Learning Method for Estimation of Life‐Long Chronic Disease Progression and Its Application to Type 2 Diabetes

    by Yamato Sano, Ryota Jin, Hideki Yoshioka, Yuki Nakazato, Hiromi Sato, Akihiro Hisaka

    Individual predictions of long‐term chronic disease progression from data of limited duration provide valuable insights into estimating patient outcomes and therapeutic needs. Statistical Restoration of Fragmented Time course (SReFT) was developed to address this challenge, yet it is computationally too intensive for large‐scale datasets. Although diabetes is a representative chronic disease with significant medical needs, it has been challenging to analyze long‐term changes using large‐scale patient data due to this limitation. In this study, we aimed to develop a new method (SReFT‐machine learning, SReFT‐ML) by applying machine learning to the concept of SReFT, and to confirm its performance using synthetic data and the data from a clinical trial, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial ( N = 10,251). SReFT‐ML has successfully analyzed both synthetic and clinical data, and reconstructed biomarker trajectories over a 30‐year period in patients with diabetes. Decreases in diastolic blood pressure and renal function may be important indicators of disease progression. Furthermore, although age and mortality data were not included in the model, survival analysis demonstrated a clear trend of hazard increases in mortality and diabetes‐related outcomes with disease progression. This study introduced machine learning to enhance long‐term disease progression modeling. The resulting model characterized a 30‐year trajectory of disease risk in diabetes. The results provide a clinically meaningful hypothesis that incorporating systemic factors such as renal function and blood pressure, in addition to classic glycemic control, may enhance comprehensive diabetes care. Trial Registration: ClinicalTrials.gov number: NCT00000620


  • Open Access

    Adjuvant Chemotherapy for Gastric Cancer may Worsen Prognosis in Elderly Women: Retrospective Analysis of Individual Patient Data from the CLASSIC Study

    by Fumitaka Noji, Hideki Yoshioka, Ryota Jin, Hiroto Hatakeyama, Hiromi Sato, Akihiro Hisaka

    Purpose: This research aimed to identify significant prognostic factors that interact with the treatment effect of capecitabine and oxaliplatin (CapeOX), based on individual patient data from the CLASSIC study (NCT00411229), which evaluated the efficacy of adjuvant chemotherapy for gastric cancer. Methods: Stepwise variable selection of prognostic factors was performed using the Cox proportional hazards model, with patient data from 519 CapeOX-treated and 514 untreated patients. Results: For all-cause mortality, older women (≥ 55 years) with a serum albumin level ≥ 4.0 g/dL were identified as significant prognostic factors interacting with CapeOX treatment, and unexpectedly, the treatment was associated with poor outcomes in this group. The prognostic significance of serum albumin levels was primarily attributed to the particularly poor survival outcomes observed in untreated patients with serum albumin < 4.0 g/dL. Tumor stage and lymph node status were prognostic factors that interacted with treatment for disease-free survival (DFS). The results showed that in patients with tumor stage (T) ≥ T3 and lymph node metastasis (N) < N2, improvement in DFS with CapeOX was not significant. Conclusion: As this was a post-hoc analysis, the results should be interpreted as hypothesis-generating rather than definitive. Nevertheless, the findings suggest the need for a more detailed consideration of patient baseline characteristics when determining the adjuvant chemotherapy strategy for gastric cancer.


  • Buffer compositions strongly impact the in vitro assessment of CYP fraction metabolized using human liver microsomes or expressed isoenzymes

    by Yuta Tamemoto, Yukihiro Shibata, Natsumi Hashimoto, Aoi Yoshitomo, Shizuka Hozuki, Keita Takahashi, Hana Kumemura, Hiroto Hatakeyama, Hiromi Sato, Akihiro Hisaka


  • Open Access

    Promoting Research on Modeling and Simulation

    by Akihiro Hisaka

    As I recently retired from Chiba University, I would like to describe how I began my research career, some of my accomplishments in the research field of modeling and simulation, and future prospects in this area. Here, I discuss the research topics of drug interactions, the oral absorption of drugs, analyses of between-group and individual differences in pharmacokinetics based on the theories of physiologically-based pharmacokinetics and population pharmacokinetics, and my roles in implementation of the drug interaction guideline. Furthermore, I also discuss modeling topics unrelated to pharmacokinetics, i.e., the analyses of the long-term progression of chronic diseases, such as Alzheimer's disease, Parkinson's disease, and chronic obstructive pulmonary disease using individual patient information; the spread of the coronavirus disease 2019 (COVID-19) pandemic; and prognostic factors of chronic heart failure with the view towards personalized medicine. After completing my Master's course at Hokkaido University, I joined a pharmaceutical company and worked as a pharmacokinetics researcher for 21 years, while obtaining my doctoral degree. I spent the next 9 years as a hospital pharmacist focusing on scientific research at the University of Tokyo Hospital, and the last 10 years as a Professor of Clinical Pharmacology and Pharmacometrics at Chiba University. My career is, therefore, characterized by involvement in pharmaceutical sciences from many different perspectives. This description focuses rather on the background of the studies than scientific details.

  • Open Access

    Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

    by Hiromi Sato, Ayana Ishikawa, Hideki Yoshioka, Ryota Jin, Yamato Sano, Akihiro Hisaka

    This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin—can be explained in a unified manner based on their ability to promote urinary glucose excretion (UGE). Information on HbA1c reduction at various doses of each SGLT2i was collected from literatures on randomized controlled trials and was normalized based on the daily UGE data from phase I studies. After normalizing doses, the dose–response relationship of HbA1c reduction of most of SGLT2is was represented by a unified nonlinear mixed-effect model, with the estimated maximum HbA1c (%) reduction (Emax) of 0.796 points, whereas covariate analysis showed that canagliflozin had a 1.33-fold higher Emax than those of the other drugs. Other covariates included baseline HbA1c levels, body weight, disease duration, prior treatment, and renal function. Findings from this study would influence drug selection and adjustment in clinical practice. As with SGLT2is, in cases where the efficacy cannot be easily evaluated but an appropriate pharmacodynamic marker was assessed in early clinical trials, similar approaches for other drug classes can guide strategic and evidence-based dose selection in phase III trials.


  • Open Access

    Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variants

    by Ryota Jin, Hideki Yoshioka, Hiromi Sato, Akihiro Hisaka

    As Parkinson's disease (PD) progresses, there are multiple biomarker changes, and sex and genetic variants may influence the rate of progression. Data‐driven, long‐term disease progression model analysis may provide precise knowledge of the relationships between these risk factors and progression and would allow for the selection of appropriate diagnosis and treatment according to disease progression. To construct a long‐term disease progression model of PD based on multiple biomarkers and evaluate the effects of sex and leucine‐rich repeat kinase 2 (LRRK2) mutations, a technique derived from the nonlinear mixed‐effects model (Statistical Restoration of Fragmented Time course [SReFT]) was applied to datasets of patients provided by the Parkinson's Progression Markers Initiative. Four biomarkers, including the Unified PD Rating Scale, were used, and a covariate analysis was performed to investigate the effects of sex and LRRK2‐related mutations. A model of disease progression over ~30 years was successfully developed using patient data with a median of 6 years. Covariate analysis suggested that female sex and LRRK2 G2019S mutations were associated with 21.6% and 25.4% significantly slower progression, respectively. LRRK2 rs76904798 mutation also tended to delay disease progression by 10.4% but the difference was not significant. In conclusion, a long‐term PD progression model was successfully constructed using SReFT from relatively short‐term individual patient observations and depicted nonlinear changes in relevant biomarkers and their covariates, including sex and genetic variants.


  • Open Access

    Exercise training outcomes in patients with chronic heart failure with reduced ejection fraction depend on patient background

    by Yukako Soejima, Hideki Yoshioka, Sayuri Guro, Hiromi Sato, Hiroto Hatakeyama, Yasunori Sato, Yoshihide Fujimoto, Naohiko Anzai, Akihiro Hisaka

    Background: The aim of this study was to identify significant factors affecting the effectiveness of exercise training using information of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) study.Methods: Background factors influencing the effect of exercise training were comprehensively surveyed for 2,130 patients by multivariable Cox regression analysis with the stepwise variable selection, and only significant factors were selected that were statistically distinguished from dummy noise factors using the Boruta method.Results: The analysis suggested that the use of beta-blockers, pulse pressure, hemoglobin level, electrocardiography findings, body mass index, and history of stroke at baseline potentially influenced the exercise effect on all-cause death (AD). Therefore, a hypothetical score to estimate the effect of exercise training was constructed based on the analysis. The analysis suggested that the score is useful in identifying patients for whom exercise training may be significantly effective in reducing all-caused death and hospitalization (ADH) as well as AD. Such a subpopulation accounted for approximately 40% of the overall study population. On the other hand, in approximately 45% of patients, the effect of exercise was unclear on either AD or ADH. In the remaining 15% of patients, it was estimated that the effect of exercise might be unclear for ADH and potentially rather increase AD.Conclusions: This study is the first analysis to comprehensively evaluate the effects of various factors on the outcome of exercise training in chronic heart failure, underscoring the need to carefully consider the patient's background before recommending exercise training. However, it should be noted that exercise training can improve many outcomes in a wide variety of diseases. Therefore, given the limitations involved in post-hoc analyses of a single clinical trial, the characteristics of patients to whom the results of this analysis can be applied need attention, and also further research is necessary on the relationship between the degree of exercise and the outcomes. A new clinical trial would be needed to confirm the factors detected and the appropriateness of the score.


  • Open Access

    Model‐based meta‐analysis of ethnic differences and their variabilities in clearance of oral drugs classified by clearance mechanism

    by Hiromi Sato, Rika Marutani, Ryota Takaoka, Daniel Mori‐Fegan, Xinying Wang, Kazuya Maeda, Hiroyuki Kusuhara, Hiroshi Suzuki, Hideki Yoshioka, Akihiro Hisaka

    In this study, the ethnic ratios (ERs) of oral clearance between Japanese and Western populations were subjected to model‐based meta‐analysis (MBMA) for 81 drugs evaluated in 673 clinical studies. The drugs were classified into eight groups according to the clearance mechanism, and the ER for each group was inferred together with interindividual variability (IIV), interstudy variability (ISV), and inter‐drug variability within a group (IDV) using the Markov chain Monte Carlo (MCMC) method. The ER, IIV, ISV, and IDV were dependent on the clearance mechanism, and, except for particular groups such as drugs metabolized by polymorphic enzymes or their clearance mechanism is not confirmative, the ethnic difference was found to be generally small. The IIV was well‐matched across ethnicities, and the ISV was approximately half of the IIV as the coefficient of variation. To adequately assess ethnic differences in oral clearance without false detections, phase I studies should be designed with full consideration of the mechanism of clearance. This study suggests that the methodology of classifying drugs based on the mechanism that causes ethnic differences and performing MBMA with statistical techniques such as MCMC analysis is helpful for a rational understanding of ethnic differences and for strategic drug development.